CRISPR Therapeutics Balances CASGEVY Momentum With Early Pipeline Uncertainty [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
CRISPR Therapeutics (NasdaqGM:CRSP) reports strong commercial momentum for its gene therapy CASGEVY, with patient initiations nearly tripling year over year. The company is preparing a regulatory submission in the first half of 2026 to expand CASGEVY's label to pediatric patients. Cardiovascular candidate CTX310 showed positive early clinical data, published in the New England Journal of Medicine, and is progressing into Phase 1b trials. For you as an investor, CRISPR Therapeutics sits at the intersection of gene editing and commercialized therapies, with CASGEVY already in the market and early pipeline assets advancing. The recent updates speak directly to how its core product and pipeline programs are moving through clinical and regulatory milestones, rather than just financial headlines. This can help frame how you think about the company's mix of approved therapy exposure and earlier stage development risk. Looking ahead, the planned pediatric submission for CASGEVY and t
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Is CRISPR Therapeutics Stock a Buy Now? [Yahoo! Finance]Yahoo! Finance
- Is Crispr Therapeutics (CRSP) The Best Gene-Editing Stock to Buy Now? [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics (CRSP) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $110.00 price target on the stock, up from $105.00.MarketBeat
- A Look At CRISPR Therapeutics (CRSP) Valuation After Upsized US$550 Million Convertible Note Offering [Yahoo! Finance]Yahoo! Finance
- Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 2/12/26 - Miss
CRSP
Sec Filings
- 3/17/26 - Form 4
- 3/17/26 - Form 4
- 3/17/26 - Form 4
- CRSP's page on the SEC website